Novavax Inc (Novavax) discovers, develops and commercializes recombinant nanoparticle vaccines for the treatment of infectious diseases. Its product candidates include vaccines to prevent respiratory syncytial virus, influenza, COVID-19, Ebola virus, Middle East respiratory syndrome, and severe acute respiratory syndrome. The company operates through one reportable segment, the development of recombinant vaccines.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

The company’s R&D activities focus on the development of vaccines for the treatment of infectious diseases including COVID-19, seasonal influenza, respiratory syncytial virus, Ebola virus, Middle East respiratory syndrome, severe acute respiratory syndrome and other diseases. In FY2022, the company spent US$1235.3 million and has 63% of employees engaged on its R&D. The company has R&D facilities in Gaithersburg, Maryland and Uppsala, Sweden. As of December 31, 2022, the company had over 550 US patents and corresponding foreign patents and patent applications related to its vaccines and vaccine-related technologies.